Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial results

PeproMene Bio publishes Phase 1 CAR T results

Analysis based on 8 articles · First reported Jul 20, 2026 · Last updated Sep 08, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The publication of positive Phase 1 data in a prestigious journal like The Lancet could enhance PeproMene Bio's credibility and valuation, potentially attracting investment and partnerships. The promising efficacy and safety profile of PMB-CT01 may also impact the competitive landscape for CAR T-cell therapies, affecting established players in the oncology space.

Biotechnology Pharmaceuticals Healthcare

PeproMene Bio announced the publication in The Lancet of results from its Phase 1 clinical trial of PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial demonstrated durable complete responses in 7 of 9 treated patients (80%), including 4 of 6 patients who had progressed after prior CD19-directed CAR T-cell therapy. All complete responses remained ongoing at data cutoff, with the longest lasting 35 months. The therapy showed a favorable safety profile, with all cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome events limited to Grade 1. Based on these results, the trial expanded from City of Hope to multiple additional medical centers across the United States. The first patient in the expansion phase, who had triple-hit high-grade B-cell lymphoma after CD19 CAR T failure, also achieved a complete response. The Institute for Follicular Lymphoma Innovation had committed up to $11 million in December 2024 to support clinical development. PeproMene Bio has licensed intellectual property from City of Hope.

100 PeproMene Bio published results
priv
As the developer of PMB-CT01, PeproMene Bio is the primary beneficiary. The positive results and publication could significantly boost its prospects for funding, partnerships, and eventual commercialization.
Importance 100.0 Sentiment 90.0
ngo
City of Hope is the coordinating center and manufacturing site for the trial and has licensed IP to PeproMene Bio. The success enhances its reputation in cancer research and may lead to further collaborations and licensing revenue.
Importance 70.0 Sentiment 60.0
ngo
IFLI provided up to $11 million in funding to support the clinical development of PMB-CT01. The positive results validate its investment and support its mission to advance treatments for follicular lymphoma.
Importance 50.0 Sentiment 60.0
per
As scientific founder of PeproMene Bio, Larry W. Kwak is a key figure in the development of PMB-CT01. The positive results enhance his professional standing and may lead to further research opportunities.
Importance 40.0 Sentiment 50.0
per
Stephen Forman, as co-author and director at City of Hope, contributed to the trial's success. The results bolster his reputation in hematologic malignancies research.
Importance 30.0 Sentiment 50.0
per
Mehrdad Mobasher, as Executive Partner at IFLI, supported the funding and is encouraged by the results. The success reflects positively on his role in advancing CAR T-cell therapy.
Importance 20.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.